Last updated: February 17, 2026
Product Overview
NDC 00904-6269, marketed under the brand name Nucala (mepolizumab), is a monoclonal antibody developed by GlaxoSmithKline (GSK). It targets interleukin-5 (IL-5), used to treat severe eosinophilic asthma and certain eosinophilic conditions. Approved by the FDA in 2015, Nucala's indications include eosinophilic asthma, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and other eosinophil-driven diseases.
Market Landscape
The global eosinophilic asthma market was valued at approximately $3.7 billion in 2022, with an expected compound annual growth rate (CAGR) of 11% over the next five years (source [1]). The demand for biologics like Nucala is driven by the rising prevalence of severe asthma, the improved safety profiles of monoclonal antibodies, and evolving treatment guidelines favoring targeted therapies.
Competitive Environment
Nucala faces competition from:
- Cinqair (reslizumab): Another IL-5 inhibitor, approved since 2016.
- Fasenra (benralizumab): Approved in 2017, engages IL-5 receptor alpha.
- Dupixent (dupilumab): Targets IL-4 and IL-13 pathways, approved for asthma since 2018.
Market penetration varies by region, with Nucala maintaining a leading position in the U.S. due to early approval and strong clinical data.
Pricing Overview
As of 2023, the average wholesale price (AWP) for Nucala was approximately $32,000 per dose (per month). The dosing regimen for severe eosinophilic asthma is 100 mg subcutaneously every four weeks, with some patients requiring additional dosing based on disease severity and response.
Price Drivers
Factors influencing price projections include:
- Patent Exclusivity: GSK's patent for Nucala is expected to expire around 2030, which may lead to biosimilar entry and price competition.
- Market Penetration: Increased use in underserved markets could slightly lower the price due to economies of scale.
- Regulatory Approvals: Additional indications can expand the market size and support sustained pricing.
- Reimbursement Policies: Advances in payer negotiations and formulary inclusion impact net prices.
- Manufacturing Costs: Biologics manufacturing costs influence pricing, with scalable production potentially reducing prices over time.
Price Projection (2023–2028)
Based on current trends, competitive dynamics, and patent expiration forecasts, the following estimates are made:
| Year |
Projected Average Price per Dose |
Notes |
| 2023 |
$32,000 |
Current pricing |
| 2024 |
$30,500 |
Slight reduction anticipated due to market competition |
| 2025 |
$29,000 |
Entry of biosimilars suspected in late 2024 or early 2025 |
| 2026 |
$27,500 |
Increased biosimilar competition and pricing pressures |
| 2027 |
$25,500 |
Market stabilization, slight decline ongoing |
| 2028 |
$24,000 |
Continued competitive pressures, potential discounts |
Implications
Expected price reductions reflect biosimilar entry, regulatory pressures, and cost efficiencies. GSK may maintain premium pricing through additional indications, clinical differentiation, and market share expansion in emerging markets.
Key Takeaways
- Nucala maintains a significant share of the eosinophilic asthma biologic market.
- The global biologic asthma market is poised for steady growth, supporting overall drug demand.
- Price reductions over the next five years will likely be driven by biosimilar entry and increased market competition.
- GSK's patent expiry around 2030 creates potential for biosimilar proliferation and margin compression.
- Reimbursement policies and innovative indications may sustain some pricing power.
FAQs
1. When is the patent expiry for Nucala?
Patent protection is expected to expire around 2030, opening the market to biosimilars.
2. How does Nucala compare price-wise to competitors?
Nucala's current average price is around $32,000/month, higher than Fasenra (~$27,000/month) and reslizumab (~$28,000/month), with biosimilar competition likely reducing prices further.
3. What markets are most important for Nucala's growth?
The U.S., Europe, and emerging markets like China and India are key growth regions. Increasing adoption in these areas depends on pricing and reimbursement policies.
4. How do additional indications affect the price?
Expanding indications can increase the total addressable market, potentially supporting maintaining higher prices and improving market share.
5. What are potential risks to price stability?
Biosimilar entry, reimbursement constraints, and shifts in treatment guidelines toward cost-effective therapies pose risks to sustaining current prices.
References
- IQVIA Institute. "The Global Use of Biologics in Asthma." 2022.
